Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

amneal pharmaceuticals llc - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 95 mg - rytary is indicated for the treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. rytary is contraindicated in patients: - currently taking a nonselective monoamine oxidase (mao) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective mao inhibitor. hypertension can occur if these drugs are used concurrently [see drug interactions (7.1)] . risk summary there are no adequate data on the developmental risk associated with the use of rytary in pregnant women. in animal studies, carbidopa-levodopa has been shown to be developmentally toxic (including teratogenic effects) at clinically relevant doses (see data). the estimated background risk of major birth defects and miscarriage in the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% a

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - carbidopa monohydrate 47,25 mg - eq. carbidopa 43,75 mg; levodopa 175 mg; entacapone 200 mg - film-coated tablet - 175 mg - 43,75 mg - 200 mg - levodopa 175 mg; carbidopa monohydrate 47.25 mg; entacapone 200 mg - levodopa, decarboxylase inhibitor and comt inhibitor

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - carbidopa monohydrate 13,5 mg - eq. carbidopa 12,5 mg; levodopa 50 mg; entacapone 200 mg - film-coated tablet - 50 mg - 12,5 mg - 200 mg - levodopa 50 mg; carbidopa monohydrate 13.5 mg; entacapone 200 mg - levodopa, decarboxylase inhibitor and comt inhibitor

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - carbidopa monohydrate 27 mg - eq. carbidopa 25 mg; levodopa 100 mg; entacapone 200 mg - film-coated tablet - 100 mg - 25 mg - 200 mg - levodopa 100 mg; carbidopa monohydrate 27 mg; entacapone 200 mg - levodopa, decarboxylase inhibitor and comt inhibitor

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - carbidopa monohydrate 40,5 mg - eq. carbidopa 37,5 mg; levodopa 150 mg; entacapone 200 mg - film-coated tablet - 150 mg - 37,5 mg - 200 mg - levodopa 150 mg; carbidopa monohydrate 40.5 mg; entacapone 200 mg - levodopa, decarboxylase inhibitor and comt inhibitor

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - carbidopa monohydrate 54 mg - eq. carbidopa 50 mg; levodopa 200 mg; entacapone 200 mg - film-coated tablet - 200 mg - 50 mg - 200 mg - levodopa 200 mg; carbidopa monohydrate 54 mg; entacapone 200 mg - levodopa, decarboxylase inhibitor and comt inhibitor

Īrija - angļu - HPRA (Health Products Regulatory Authority)

orion corporation - carbidopa monohydrate; levodopa - tablet - levodopa and decarboxylase inhibitor

Īrija - angļu - HPRA (Health Products Regulatory Authority)

orion corporation - carbidopa monohydrate; levodopa - tablet - levodopa and decarboxylase inhibitor